Cellebrite DI Ltd. (NASDAQ:CLBT) Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC boosted its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 46.2% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 306,287 shares of the company's stock after buying an additional 96,758 shares during the period. SG Americas Securities LLC owned approximately 0.13% of Cellebrite DI worth $5,951,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Gen Wealth Partners Inc acquired a new stake in Cellebrite DI in the fourth quarter valued at approximately $85,000. NewEdge Advisors LLC grew its position in Cellebrite DI by 600.7% in the fourth quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock valued at $86,000 after acquiring an additional 3,352 shares in the last quarter. Polen Capital Management LLC acquired a new stake in Cellebrite DI in the fourth quarter valued at approximately $222,000. Victory Capital Management Inc. acquired a new stake in Cellebrite DI in the fourth quarter valued at approximately $234,000. Finally, HighTower Advisors LLC acquired a new stake in Cellebrite DI in the fourth quarter valued at approximately $274,000. Hedge funds and other institutional investors own 45.88% of the company's stock.

Analyst Ratings Changes

Several brokerages have issued reports on CLBT. JPMorgan Chase & Co. lowered their price objective on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a research report on Monday, May 12th. Needham & Company LLC reaffirmed a "buy" rating and issued a $24.00 price objective on shares of Cellebrite DI in a research report on Friday, June 6th. Finally, Lake Street Capital increased their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, February 14th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $22.43.

Cellebrite DI Stock Performance

Shares of CLBT stock traded down $0.46 during mid-day trading on Friday, reaching $15.78. 1,338,342 shares of the company were exchanged, compared to its average volume of 1,475,929. Cellebrite DI Ltd. has a fifty-two week low of $11.47 and a fifty-two week high of $26.30. The company has a market capitalization of $3.78 billion, a P/E ratio of -11.35, a P/E/G ratio of 4.27 and a beta of 1.32. The business's 50 day simple moving average is $18.14 and its 200 day simple moving average is $19.95.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported $0.10 earnings per share for the quarter, topping analysts' consensus estimates of $0.09 by $0.01. Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. The business had revenue of $107.55 million during the quarter, compared to the consensus estimate of $109.36 million. During the same quarter last year, the company earned $0.08 earnings per share. The business's quarterly revenue was up 20.0% compared to the same quarter last year. On average, analysts forecast that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.